



Clinical trial results:

Prospective, Single-centre, Double-Blind, Randomised, Placebo-controlled Study Evaluating Efficacy of Adalimumab + Methotrexate Compared with Placebo + Methotrexate in Patients with Early Oligoarthritis

Summary

EudraCT number	2008-004877-17
Trial protocol	GB
Global end of trial date	16 January 2017

Results information

Result version number	v1 (current)
This version publication date	07 August 2020
First version publication date	07 August 2020
Summary attachment (see zip file)	ADEOS End of Trial report 8-10-18 (ADEOS End of Trial report 8-10-18.pdf)

Trial information

Trial identification

Sponsor protocol code	RR08/8685
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University of Leeds
Sponsor organisation address	Woodhouse Lane, Leeds, United Kingdom, LS2 9JT
Public contact	Dr Ai Lyn Tan, University of Leeds, 0113 3924884, A.L.Tan@leeds.ac.uk
Scientific contact	Dr Ai Lyn Tan, University of Leeds, 0113 3924884, A.L.Tan@leeds.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 January 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	16 January 2017
Global end of trial reached?	Yes
Global end of trial date	16 January 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the proportion of patients who achieve clinical remission after 24 weeks of adalimumab and methotrexate (MTX) therapy compared to methotrexate monotherapy in the management of early, persistent oligoarthritis. The defining criteria for clinical remission is absence of tender/swollen joints & CRP < 5mg/ml)

Protection of trial subjects:

Before being enrolled in the clinical study, subjects must consent to participate after the nature, scope, and possible consequences of the clinical study have been explained in a form understandable to them.

An informed consent document that includes both information about the study and the consent form will be prepared and given to the subject. This document will contain all the elements required by ICH E6 Guideline for Good Clinical Practice and any additional elements required by local regulations. The document must be in a language understandable to the subject and must specify who informed the subject. Where required by local law, the person who informs the subject must be a physician.

One copy of the informed consent document will be kept in the patient's medical notes.

Further, a signed copy will be given to the patient.

The patient will be given at least 24 hours to consider this information after initially receiving the patient information before the consent is taken. This process will be documented in the patient notes. After reading the informed consent document, the subject must give consent in writing. The subject's consent must be confirmed at the time of consent by the personally dated signature of the subject and by the personally dated signature of the person conducting the informed consent discussions.

A copy of the signed consent document must be given to the subject. The original signed consent document will be retained by the investigator.

The investigator will not undertake any measures specifically required only for the clinical study until valid consent has been obtained.

The investigator must inform the subject's primary physician about the subject's participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 December 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 99999
Worldwide total number of subjects	99999
EEA total number of subjects	99999

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	99999
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects presenting at the rheumatology clinic who meet all of the screening criteria will be considered for enrolment into the study. A verbal explanation of the trial and Patient Information Sheet will be provided by the attending medical staff for the patient to consider.

Pre-assignment

Screening details:

Assenting patients will then be formally assessed for eligibility and invited to provide informed, written consent. The written consent will be taken by a clinician with the appropriate skills and training to do so, who has signed and dated the staff authorisation/delegation log. The process of obtaining written consent will be clearly documented

Period 1

Period 1 title	Main Trial Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	adalimumab and methotrexate (MTX) combination therapy

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

40mg 2-weekly

Investigational medicinal product name	Methotrexate (with folic acid combination therapy)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

25mg weekly

Arm title	methotrexate monotherapy
------------------	--------------------------

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Methotrexate (with folic acid combination therapy)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

25mg weekly

Number of subjects in period 1	adalimumab and methotrexate (MTX) combination therapy	methotrexate monotherapy
Started	99998	1
Completed	99998	1

Baseline characteristics

Reporting groups

Reporting group title	Main Trial Period
-----------------------	-------------------

Reporting group description: -

Reporting group values	Main Trial Period	Total	
Number of subjects	99999	99999	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	99999	99999	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	99999	99999	
Male	0	0	

End points

End points reporting groups

Reporting group title	adalimumab and methotrexate (MTX) combination therapy
Reporting group description: -	
Reporting group title	methotrexate monotherapy
Reporting group description: -	

Primary: Number of patients in clinical remission at week 24

End point title	Number of patients in clinical remission at week 24 ^[1]
End point description:	number of patients in clinical remission at week 24 (defined as absence of tender/swollen joints & CRP < 5mg/L)
End point type	Primary
End point timeframe:	screening- week 24

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: A full data set to satisfy the requirements for the EudraCT upload is unavailable as the data analysis is incomplete for this trial. Following discussion with the UK regulator the MHRA it was agreed that the trial teams would not pursue publication for this trial and results analysis was halted. It was agreed with the MHRA in September 2019 that a full data upload on EudraCT is not required.

End point values	adalimumab and methotrexate (MTX) combination therapy	methotrexate monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[2]	0 ^[3]		
Units: patients				

Notes:

[2] - data analysis is incomplete for this trial.

[3] - data analysis is incomplete for this trial.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

SAE's were assessed at every study visit, and were reported within the regulatory guidelines

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	4
--------------------	---

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: A full data set to satisfy the requirements for the EudraCT upload is unavailable as the data analysis is incomplete for this trial. Following discussion with the UK regulator the MHRA it was agreed that the trial teams would not pursue publication for this trial and results analysis was halted.

It was agreed with the MHRA in September 2019 that a full data upload on EudraCT is not required.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 January 2017	The trial had multiple substantial amendments, but a full data set to satisfy the requirements for the EudraCT upload is unavailable as the data analysis is incomplete for this trial. Following discussion with the UK regulator the MHRA it was agreed that the trial teams would not pursue publication for this trial and results analysis was halted. It was agreed with the MHRA in September 2019 that a full data upload on EudraCT is not required.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

A full data set to satisfy the requirements for the EudraCT upload is unavailable as the data analysis is incomplete for this trial. Following discussion with the UK regulator the MHRA it was agreed that the trial teams would not pursue publication
--

Notes: